The United States of America, As Represented by the Secretary, Department of Health and Human Services

Columbia University

Duke University

Dartmouth College

Glaxosmithkline Biologicals Sa

Institute for Research in Biomedicine

Korea Center for Disease Control and Prevention

Leland Stanford Junior University

University of Pennsylvania

The Scripps Research Institute

Boston University

Triad National Security, LLC

International Aids Vaccine Initiative

University of the Witwatersrand, Johannesburg

National Health Laboratory Service

John Mascola

Barney S Graham

Peter D Kwong

Wing-Pui Kong

Ivelin Georgiev

Gwo-Yu Chuang

Guillaume Stewart-Jones

Aliaksandr Druz

Yaroslav Tsybovsky

Lingshu Wang

Li Ou

Bryan Edward Jones

Christopher Carl Frye

Wei Shi

Gary J Nabel

Barton F Haynes

Antonio Lanzavecchia

Dennis R Burton

Baoshan Zhang

Tongqing Zhou

Michael Gordon Joyce

Julian Davies

Qing Chai

Kizzmekia S Corbett

Ulrich Baxa

Davide Corti

Hua-Xin Liao

Bette T Korber

Zhi-yong Yang

Masaru Kanekiyo

Sanjay K Phogat

Wayne C Koff

Yongping Yang

Cheng Cheng

Jeffrey C Boyington

Mark Connors

Young Do Kwon

Marie Pancera

Beatrice H Hahn

Richard Schwartz

George M Shaw

Jason Scott McLellan

Pascal Raymond Georges Poignard

Melissa Danielle De Jean De St Marcel Simek-Lemos

Xueling Wu

Feng Gao

Julie Ledgerwood

Kai Xu

Cinque Soto

Jinghe Huang

Rebecca S Rudicell

Jiang Zhu

Jeffrey Streetman Boyles

Ganapathy Gopalrathnam

Jörg Hendle

John Michael Sauder

Stefanie Zentelis

Olubukola Abiona

Anna Pustilnik

Wing-pui Kong

Denisa Foster

Krithika Muthuraman

Yi Zhang

Kathryn Westendorf

Kevin Jepson

Ester Falconer

Mallika Sastry

Joseph Van Galen

Gilad Ofek

Man Chen

Jason Gorman

Thomas B Kepler

Paul Thomas

Syed M Moin

Scott D Boyd

Dong Yu

Rebecca M Lynch

Priyamvada Acharya

Lawrence Shapiro

Rita Chen

Emily Rundlet

Xuejun Chen

Hongying Duan Holdsworth

Krisha McKee

Theodore C Pierson

Kimberly A Dowd

Sijy O'Dell

Robert Bailer

Mark Louder

Mangaiarkarasi Asokan

Byong Ha Kang

Elise Ishida

Anqi Zheng

Jonathan Cooper

Lynn Morris

Kevin Carlton

Nicole Amy Doria-Rose

Michael Bender

Amarendra Pegu

Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

HIV-1 ENV fusion peptide immunogens and their use

Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

Neutralizing antibodies to GP120 and their use

Antibodies that bind SARS-CoV spike protein, SARS-CoV-2 spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

Anti-coronavirus antibodies and methods of use

HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.

Recombinant HIV-1 envelope proteins and their use

The present invention relates to monoclonal antibodies for a spike protein of the Middle East respiratory syndrome coronavirus (MERS-CoV), and a use thereof. Particularly, monoclonal antibodies 77-A5, 77-A6, 90-A3, 90-A9, 90-B2, 90-B7, 90-C4, 90-E5, 90-E6, 90-F1 and 90-F2 according to the present invention have excellent attachment force with respect to a full-length spike protein of MERS-CoV and the S1 domain of the protein, and, of the monoclonal antibodies, the monoclonal antibodies 90-F1, 90-E5, 90-E6, 90-F2, 77-A5 and 77-A6 have excellent attachment force with respect to an RBD antigen of MERS-CoV. Also, the antibodies 77-A5, 77-A6, 90-E5, 90-E6, 90-F1 and 90-F2 exhibit neutralizing capacity with respect to a MERS pseudovirus and MERS-CoV, and the antibodies 90-B2 and 90-B7 exhibit neutralizing capacity only with respect to MERS-CoV. Further, the monoclonal antibodies have a particular monomeric form, and have excellent stability and thus may be useful for treating or diagnosing MERS.

Monoclonal antibody for spike protein of middle east respiratory syndrome coronavirus, and use thereof

Embodiments of immunogenic conjugates including the HIV-1 Env fusion peptide and methods of their use and production are disclosed. In several embodiments, the immunogenic conjugates can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use

Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use

Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.

Self-assembling insect ferritin nanoparticles

Embodiments of immunogens comprising a recombinant Nipah virus (NiV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also provided are embodiments of immunogens comprising chimeric proteins comprising the recombinant NiV F ectodomain trimer and one or more G ectodomains, a multimer of NiV G ectodomains, and protein nanoparticles comprising the recombinant NiV F ectodomain trimer or an NiV G ectodomain. Also disclosed are nucleic acids encoding the immunogens and methods of their production. Methods for inducing an immune response in a subject by administering a disclosed immunogen to the subject are also provided. In some embodiments, the immune response treats or inhibits NiV infection in a subject.

Nipah virus immunogens and their use

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

Prefusion RSV F proteins and their use

Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.

Prefusion PIV F immunogens and their use

Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen.

Zika viral antigen constructs

Antibodies and antigen binding fragments that specifically bind to HIV-1 Env and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

Neutralizing antibodies to HIV-1 Env and their use

Antibodies that bind SARS-CoV Spike protein, SARS-CoV-2 Spike protein, and methods of using same for treating or preventing conditions associated with SARS or COVID-19 and for detecting SARS-CoV or SARS-CoV-2.

Growing community of inventors

Bethesda, MD, United States of America

John Mascola